Skip to content
Aminoscope
Head-to-head

GHRP-6 vs Ipamorelin

Same receptor, opposite design intent. GHRP-6 is the blunt first-generation tool whose hallmark is hunger; ipamorelin was engineered to release GH with minimal spillover.

By Julian RothResearch & dataUpdated November 2026

Short answer

GHRP-6 and ipamorelin both have human clinical data, so the deciding factor is what you want them for. GHRP-6 suits someone focused on muscle and recovery, while ipamorelin is aimed at muscle and fat loss. Ipamorelin failed its primary endpoint in a randomized trial for bowel recovery after surgery; no muscle or fat-loss outcome trials.

GHRP-6

Clinical data

The GHRP-6 evidence review explains what has been studied. Pulses GH short-term, but its most reliable real-world effect is a surge in appetite; no long-term human outcomes and not approved.

Ipamorelin

Clinical data

The Ipamorelin evidence review explains what has been studied. Raises GH, but failed its one rigorous human efficacy RCT; no body-composition outcome data.

GHRP-6 vs Ipamorelin: head to head

The evidence matrix shows the source behind each grade and the use that grade applies to. A grade for one use does not carry over to every claim about the same molecule.

FDA status / approved use

GHRP-6

Not FDA-approved; sold as a gray-market research peptide

Ipamorelin

Not approved for its marketed uses; sold as unregulated research-use-only products
Marketed for

GHRP-6

Muscle, recovery, 'anti-aging'

Ipamorelin

Muscle, fat loss, 'anti-aging'
Outcome areas

GHRP-6

Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan

Ipamorelin

Muscle / strength / lean mass; Weight loss / appetite; Longevity / lifespan
Evidence grade

GHRP-6

Clinical data

Ipamorelin

Clinical data
How it works

GHRP-6

Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormone

Ipamorelin

Selective ghrelin mimetic that triggers a growth hormone pulse
Route and dosing

GHRP-6

Injection, usually subcutaneous; also studied intravenous and oral

Ipamorelin

Injection, usually sold together with CJC-1295
Headline human result

GHRP-6

GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome data

Ipamorelin

Failed its primary endpoint in a randomized trial for bowel recovery after surgery; no muscle or fat-loss outcome trials
Strongest evidence
Key safety signal

GHRP-6

Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing

Ipamorelin

Unverified dose, purity and identity; chronic GH/IGF-1 stimulation raises unaddressed safety concerns
How it is obtained

GHRP-6

Sold gray-market as a research chemical; no approved or legitimately compounded human product

Ipamorelin

Sold gray-market as a research chemical; no approved or legitimately compounded human product

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

GHRP-6 does raise growth hormone in humans across intravenous, subcutaneous and oral routes, but it also raises ACTH and cortisol, and its most reliable real-world effect is a strong, dose-dependent increase in appetite. Ipamorelin was characterized as the first selective GH secretagogue, with little effect on cortisol or prolactin, yet when it was tested in a proper randomized trial for postoperative recovery of bowel function it missed its primary endpoint. Both are research-only with no long-term human outcome data for the uses they are marketed for, and neither has been compared against the other in a trial. The cytoprotective findings often cited for GHRP-6 are rodent work, not human outcomes. If you want a GH-axis peptide that pharmacies can still compound, sermorelin is the usual prescription route; the System Labs review shows it at $175 a month after an $89 first month.

GHRP-6 fits if

GHRP-6 is the relevant molecule if the question is ghrelin-like appetite biology or the older cross-route GH-stimulation literature.

Ipamorelin fits if

Ipamorelin is the closer match for a reader who cares specifically about a clean GH signal without the appetite and cortisol spillover.

GHRP-6 vs Ipamorelin: common questions

Is either GHRP-6 or ipamorelin FDA-approved?
No. GHRP-6 is not FDA-approved; sold as a gray-market research peptide. Ipamorelin is not approved for its marketed uses; sold as unregulated research-use-only products.
Which has stronger human evidence, GHRP-6 or ipamorelin?
Neither clearly. Both have human clinical data. The key source for GHRP-6 is Jaffe, JCEM 1993; for ipamorelin, it is Beck RCT, 2014.
What are the main safety concerns with GHRP-6 and ipamorelin?
For GHRP-6, watch for strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing. For ipamorelin, watch for unverified dose, purity and identity; chronic GH/IGF-1 stimulation raises unaddressed safety concerns.

Key studies behind each

GHRP-6

  1. Frieboes RM, Murck H, Maier P, et al. (1995). Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. PubMed 7617137
  2. Jaffe CA, Ho PJ, Demott-Friberg R, et al. (1993). Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. PubMed 7903313
  3. Frieboes RM, Murck H, Antonijevic IA, et al. (1999). Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. PubMed 10336729
  4. Bellone J, Ghizzoni L, Aimaretti G, et al. (1995). Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. PubMed 7581965

Ipamorelin

  1. Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822
  2. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683
  3. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. PubMed 19289567
  4. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. PubMed 25331030

The full evidence reviews

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHRP-6 availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Provider reviews we publish: CoreAge RxEmbodyLttlPlexusDxYucca HealthMadeMed

Related comparisons